What causes alopecia in end-stage renal disease (ESRD)?

1. US Renal Data System (USRDS). US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Available at https://www.usrds.org/2019/view/USRDS_2019_ES_final.pdf. Accessed: March 5, 2020.

2. Maurice PD. Acquired perforating dermatosis in renal patients. Nephrol Dial Transplant. 1997 Dec. 12(12):2774-5. [Medline].

3. Maurice PD, Neild GH. Acquired perforating dermatosis and diabetic nephropathy--a case report and review of the literature. Clin Exp Dermatol. 1997 Nov. 22(6):291-4. [Medline].

4. Farrell AM. Acquired perforating dermatosis in renal and diabetic patients. Lancet. 1997 Mar 29. 349(9056):895-6. [Medline].

5. Harman M, Aytekin S, Akdeniz S, Derici M. Kyrle's disease in diabetes mellitus and chronic renal failure. J Eur Acad Dermatol Venereol. 1998 Jul. 11(1):87-8. [Medline].

6. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979 Dec. 115(12):1409-15. [Medline].

7. Tebbe B, Mansmann U, Wollina U, et al. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol. 1997 Jul. 77(4):305-8. [Medline].

8. Lopez-Longo FJ, Monteagudo I, Gonzalez CM, Grau R, Carreño L. Systemic lupus erythematosus: clinical expression and anti-Ro/SS--a response in patients with and without lesions of subacute cutaneous lupus erythematosus. Lupus. 1997. 6(1):32-9. [Medline].

9. Walsh JS, Gross DJ. Wegener's granulomatosis involving the skin. Cutis. 1999 Sep. 64(3):183-6. [Medline].

10. Francès C, Du LT, Piette JC, et al. Wegener's granulomatosis. Dermatological manifestations in 75 cases with clinicopathologic correlation. Arch Dermatol. 1994 Jul. 130(7):861-7. [Medline].

11. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005 Sep. 84 (5):313-22. [Medline].

12. Sharma A, Sharma K. Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis. J Clin Exp Hepatol. 2013 Sep. 3 (3):204-12. [Medline].

13. Cacoub P, Lunel-Fabiani F, Du LT. Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med. 1992 Apr 1. 116 (7):605-6. [Medline].

14. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology. 1987 Oct. 38(10):769-84. [Medline].

15. Chuang TY, Brashear R, Lewis C. Porphyria cutanea tarda and hepatitis C virus: a case-control study and meta-analysis of the literature. J Am Acad Dermatol. 1999 Jul. 41(1):31-6. [Medline].

16. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999 Mar. 106(3):347-54. [Medline].

17. Szende B, Toth A, Perner F, Nagy K, Takacs K. Clinicopathologic aspects of 8 Kaposi's sarcomas among 1009 renal transplant patients. Gen Diagn Pathol. 1997 Dec. 143(4):209-13. [Medline].

18. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004 Sep. 66(3):1145-52. [Medline].

19. Szczech LA, Winston JA. The impact of antiretroviral therapy on HIVAN. Kidney Int. 2004 Mar. 65(3):1114; author reply 1115. [Medline].

20. Rodriguez RA. Editorial comment: effect of HAART on HIVAN--what can the clinician expect?. AIDS Read. 2004 Aug. 14(8):446-7. [Medline].

21. Scheurer D. Rapid reversal of renal failure after initiation of HAART: a case report. AIDS Read. 2004 Aug. 14(8):443-7. [Medline].

22. Foster MH. Taking HAART in HIVAN: will protease inhibitor sparing regimens alter renal outcome?. Kidney Int. 2004 Mar. 65(3):1105-6. [Medline].

23. Wei A, Burns GC, Williams BA, et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int. 2003 Oct. 64(4):1462-71. [Medline].

24. Ideura H, Hiromura K, Hiramatsu N, Shigehara T, Takeuchi S, Tomioka M, et al. Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy. Am J Physiol Renal Physiol. 2007 Oct. 293 (4):F1214-21. [Medline].

25. Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg. 1998 Mar. 17(1):48-54. [Medline].

26. Noël LH, Zingraff J, Bardin T, Atienza C, Kuntz D, Drüeke T. Tissue distribution of dialysis amyloidosis. Clin Nephrol. 1987 Apr. 27(4):175-8. [Medline].

27. Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015 Apr. 87 (4):685-91. [Medline].

28. Bean WB. A discourse on nail growth and unusual fingernails. Trans Am Clin Climatol Assoc. 1963. 74:152-67.

29. Lindsay PG. The half-and-half nail. J Lab Clin Med. 1965. 66:892-7.

30. Leyden JJ, Wood MG. The"half-and-half nail": a uremic onychopathy. Arch Dermatol. 1972 Apr. 105(4):591-2. [Medline].

31. Cabana MD, Ensor A, Tunnessen WW Jr. Picture of the month. Half-and-half fingernails. Arch Pediatr Adolesc Med. 1998 Sep. 152(9):923-4. [Medline].

32. Glynne P, Deacon A, Goldsmith D, Pusey C, Clutterbuck E. Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria?. Am J Kidney Dis. 1999 Jul. 34(1):155-60. [Medline].

33. Berman SS, Gentile AT, Glickman MH, et al. Distal revascularization-interval ligation for limb salvage and maintenance of dialysis access in ischemic steal syndrome. J Vasc Surg. 1997 Sep. 26(3):393-402; discussion 402-4. [Medline].

34. Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis. 1994 Aug. 19(2):263-73. [Medline].

35. de Jong JJ, van Gelder T, IJzermans JN, Endtz HP, Weimar W. Atypical mycobacterium infection with dermatological manifestation in a renal transplant recipient. Transpl Int. 1999. 12(1):71-3. [Medline].

36. Sayiner A, Ece T, Duman S, Yildiz A, Ozkahya M, Kiliçaslan Z, et al. Tuberculosis in renal transplant recipients. Transplantation. 1999 Nov 15. 68(9):1268-71. [Medline].

37. Shuttleworth D, Philpot CM, Salaman JR. Cutaneous fungal infection following renal transplantation: a case control study. Br J Dermatol. 1987 Nov. 117(5):585-90. [Medline].

38. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer. Am J Transplant. 2012 Mar 15. [Medline].

39. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012 Jul 26. 367(4):329-39. [Medline].

40. Colegio OR, Hanlon A, Olasz EB, Carucci JA. Sirolimus reduces cutaneous squamous cell carcinomas in transplantation recipients. J Clin Oncol. 2013 Sep 10. 31(26):3297-8. [Medline].

41. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. 2001 Jun. 27(6):561-4. [Medline].

42. Vidal D, Alomar A. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. Clin Exp Dermatol. 2004 May. 29(3):237-9. [Medline].

43. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol. 2005 Aug. 141(8):985-93. [Medline].

44. Ulrich C, Busch JO, Meyer T, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol. 2006 Aug. 155(2):451-4. [Medline].

45. Reichrath J, Nürnberg B. Solar UV-radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs). Adv Exp Med Biol. 2008. 624:203-14. [Medline].

46. Reichrath J. Sunlight, skin cancer and vitamin D: What are the conclusions of recent findings that protection against solar ultraviolet (UV) radiation causes 25-hydroxyvitamin D deficiency in solid organ-transplant recipients, xeroderma pigmentosum, and other risk groups?. J Steroid Biochem Mol Biol. 2007 Mar. 103(3-5):664-7. [Medline].

47. DiGiovanna JJ. Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention. Transplant Proc. 1998 Sep. 30(6):2771-5; discussion 2776-8. [Medline].

48. Gibson GE, O'Grady A, Kay EW, Murphy GM. Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol. 1998 Jan. 10(1):42-7. [Medline].

49. Eberhard OK, Kliem V, Brunkhorst R. Five cases of Kaposi's sarcoma in kidney graft recipients: possible influence of the immunosuppressive therapy. Transplantation. 1999 Jan 15. 67(1):180-4. [Medline].

50. Bedani PL, Risichella IS, Strumia R, et al. Kaposi's sarcoma in renal transplant recipients: pathogenetic relation between the reduced density of Langerhans cells and cyclosporin-A therapy. J Nephrol. 1999 May-Jun. 12(3):193-6. [Medline].

51. Rubinger D, Friedlaender MM, Backenroth R, Eid A, Tochner Z. Kaposi's sarcoma after renal transplantation--withdrawal of immunosuppression or local irradiation?. Nephrol Dial Transplant. 1999 May. 14(5):1343. [Medline].

52. Traywick C, O'Reilly FM. Management of skin cancer in solid organ transplant recipients. Dermatol Ther. 2005 Jan-Feb. 18(1):12-8. [Medline].

53. Dapprich DC, Weenig RH, Rohlinger AL, et al. Outcomes of melanoma in recipients of solid organ transplant. J Am Acad Dermatol. 2008 Sep. 59(3):405-17. [Medline].

54. Dinh QQ, Chong AH. Melanoma in organ transplant recipients: the old enemy finds a new battleground. Australas J Dermatol. 2007 Nov. 48(4):199-207. [Medline].

55. Urbatsch A, Sams WM Jr, Urist MM, Sturdivant R. Merkel cell carcinoma occurring in renal transplant patients. J Am Acad Dermatol. 1999 Aug. 41(2 Pt 2):289-91. [Medline].

56. Rodriguez-Gil Y, Palencia SI, Lopez-Rios F, et al. Mycosis fungoides after solid-organ transplantation: report of 2 new cases. Am J Dermatopathol. 2008 Apr. 30(2):150-5. [Medline].

57. Adeva Andany M, Martínez W, Arnal F, et al. Transfusion-associated graft-versus-host disease in a renal transplant recipient. Nephrol Dial Transplant. 1994. 9(2):196-8. [Medline].

58. Herranz P, Pizarro A, De Lucas R, et al. High incidence of porokeratosis in renal transplant recipients. Br J Dermatol. 1997 Feb. 136(2):176-9. [Medline].

59. Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol. 1998 Oct-Nov. 8(7):459-65. [Medline].

60. Knoell KA, Patterson JW, Wilson BB. Sudden onset of disseminated porokeratosis of Mibelli in a renal transplant patient. J Am Acad Dermatol. 1999 Nov. 41(5 Pt 2):830-2. [Medline].

Julia R Nunley, MD Professor, Department of Dermatology, Virginia Commonwealth University Medical Center

Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, Women's Dermatologic Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Board of Dermatology<br/>Author for: Up-to-date.

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Edward F Chan, MD Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Daniel J Hogan, MD Clinical Professor of Internal Medicine (Dermatology), Nova Southeastern University College of Osteopathic Medicine; Investigator, Hill Top Research, Florida Research Center

Daniel J Hogan, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Contact Dermatitis Society, Canadian Dermatology Association

Disclosure: Nothing to disclose.